| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 9th February 2021 | Capital Viii, Llc Vivo | 1,933,185 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Viii, Llc Vivo | 266,948 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Viii, Llc Vivo | 17,711 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $0.07 | $1,239.77 |
| 9th February 2021 | Capital Viii, Llc Vivo | 103,372 | Open or private purchase | $17.00 | $1,757,324.00 |
| 9th February 2021 | Capital Viii, Llc Vivo | 357,353 | Open or private purchase | $17.00 | $6,075,001.00 |
| 9th February 2021 | Capital Viii, Llc Vivo | 472,296 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Viii, Llc Vivo | 1,092,080 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Viii, Llc Vivo | 62 | Open or private sale | $20.00 | $1,240.00 |
| 9th February 2021 | Capital Viii, Llc Vivo | 944,056 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Capital Viii, Llc Vivo | 14,275 | Open or private purchase | $17.00 | $242,675.00 |
Crinetics Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen Betz in 2008.
Ticker: CRNX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1658247
Employees: 68
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
